Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pol Specenier

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|May 11, 2016
Afatinib in squamous cell carcinoma of the head and neckPol Specenier, Jan Vermorken
Biologics : Targets & Therapy|June 1, 2013
Cetuximab: its unique place in head and neck cancer treatmentPol Specenier, Jan B Vermorken
Expert Review of Anticancer Therapy|July 13, 2018
Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinomaPol Specenier, Jan B Vermorken
Current Opinion in Oncology|April 7, 2007
The role of taxanes and targeted therapies in locally advanced head and neck cancerPol Specenier, Jan B Vermorken
Current Opinion in Oncology|February 16, 2010
Advances in the systemic treatment of head and neck cancersPol Specenier, Jan B Vermorken
ISRN Oncology|June 30, 2012
Biologic therapy in head and neck cancer: a road with hurdlesPol Specenier, Jan B Vermorken
Expert Review of Anticancer Therapy|April 21, 2011
Cetuximab in the treatment of squamous cell carcinoma of the head and neckPol Specenier, Jan B Vermorken
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2018
Quality of life in oropharyngeal cancer: a structured review of the literatureEvelyne Roets, Karina Tukanova, Anouk Govarts, et al.
Expert Review of Anticancer Therapy|August 30, 2013
Antineoplastic therapy-induced pulmonary toxicityAnna M Sadowska, Pol Specenier, Paul Germonpre, et al.
The Oncologist|June 30, 2010
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapyVanessa Deschoolmeester, Marc Baay, Pol Specenier, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|May 11, 2016
Afatinib in squamous cell carcinoma of the head and neckPol Specenier, Jan Vermorken
Biologics : Targets & Therapy|June 1, 2013
Cetuximab: its unique place in head and neck cancer treatmentPol Specenier, Jan B Vermorken
Expert Review of Anticancer Therapy|July 13, 2018
Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinomaPol Specenier, Jan B Vermorken
Current Opinion in Oncology|April 7, 2007
The role of taxanes and targeted therapies in locally advanced head and neck cancerPol Specenier, Jan B Vermorken
Current Opinion in Oncology|February 16, 2010
Advances in the systemic treatment of head and neck cancersPol Specenier, Jan B Vermorken
ISRN Oncology|June 30, 2012
Biologic therapy in head and neck cancer: a road with hurdlesPol Specenier, Jan B Vermorken
Expert Review of Anticancer Therapy|April 21, 2011
Cetuximab in the treatment of squamous cell carcinoma of the head and neckPol Specenier, Jan B Vermorken
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2018
Quality of life in oropharyngeal cancer: a structured review of the literatureEvelyne Roets, Karina Tukanova, Anouk Govarts, et al.
Expert Review of Anticancer Therapy|August 30, 2013
Antineoplastic therapy-induced pulmonary toxicityAnna M Sadowska, Pol Specenier, Paul Germonpre, et al.
The Oncologist|June 30, 2010
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapyVanessa Deschoolmeester, Marc Baay, Pol Specenier, et al.
Pageof 6